Related Experiment Video
Updated: Jun 20, 2026
09:19
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Obesity and thromboembolic disease.
1Department of Research, St. Joseph Mercy Oakland Hospital, Pontiac, MI 48341-5023, USA. steinp@trinity-health.org
Clinics in Chest Medicine
|August 25, 2009
Summary
Obesity is a significant risk factor for venous thromboembolism (VTE) and recurrent VTE. This condition also shows a synergistic effect with oral contraceptives, increasing VTE risk.
Area of Science:
- Hematology
- Vascular Medicine
- Obesity Medicine
Background:
- Obesity is associated with hemostatic abnormalities, including elevated plasminogen activator inhibitor-1.
- Other coagulation and platelet activation issues are noted in obese individuals.
- Circulating microparticles are frequently observed in obese patients.
Purpose of the Study:
- To investigate the association between obesity and venous thromboembolism (VTE).
- To determine if obesity is a risk factor for recurrent VTE.
- To examine potential synergistic effects between obesity and oral contraceptive use on VTE risk.
Main Methods:
- Analysis of the National Hospital Discharge Survey database.
- Epidemiological study design to assess risk factors for VTE.
- Statistical analysis to identify correlations and synergistic effects.
Main Results:
- Obesity was confirmed as a significant risk factor for VTE.
- Obesity was also identified as a risk factor for recurrent VTE.
- A synergistic effect between obesity and oral contraceptive use on VTE risk was demonstrated.
Conclusions:
- Obesity represents a substantial risk factor for both initial and recurrent VTE.
- The combination of obesity and oral contraceptives amplifies the risk of VTE.
- Clinical awareness and management strategies for VTE should consider obesity status.
Related Concept Videos
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...